TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: composite of death, HF, or MI
Endpoint domain: Mortality/survival
Primary endpoint: RPF at 1 hour after angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence rate of RCN at 48 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Peak serum creatinine level at 72 hours after contrast infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quality of intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability for LoD
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulmonary Arterial Systolic Pressure (PASP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tricuspid Regurgitant Velocity (TRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Ventricular Systolic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in modified Ashworth scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Reduction in pain scores on visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the Paced Auditory Serial Addition Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive outcomes
Primary endpoint: mortality during induction treatment
Endpoint domain: Mortality/survival
Primary endpoint: complete remission rate after second course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of severe hemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammatory response intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reports of unsafe sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of antirotavirus IgA responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: time to shock resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily amount of fluids administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure of incontinence
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient-determined continent status
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative decrease in pad score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk aesthetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Per cent of complex utterances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propositional density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total talk time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PYY3‐36 levels after GBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting ghrelin levels after diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tactile and air blast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque score (PS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported days of tenderness
Endpoint domain: Adverse events/effects
Primary endpoint: Reported days of pain
Endpoint domain: Adverse events/effects
Primary endpoint: Reported days of swelling
Endpoint domain: Adverse events/effects
Primary endpoint: Depression-anxiety factor
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of masculinity (LoM)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mini Mental State Examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Timed Up and Go performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumental Activities of Daily Living scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Discontinuation or dosage reduction of high-risk medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: self-reported history of benign breast disease (BBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: risk of future breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: teenage pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of early reactions following catheterization
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of late skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: estradiol levels suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: amenorrhea after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Genetic liability to endometriosis associated with invasive epithelial ovarian cancer
Endpoint domain: Mortality/survival
Primary endpoint: Lifetime smoking exposure associated with invasive epithelial ovarian cancer
Endpoint domain: Mortality/survival
Primary endpoint: TG (Triglycerides)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL-C (High-Density Lipoprotein Cholesterol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative survival rate of primary molars
Endpoint domain: Mortality/survival
Primary endpoint: Recognition and evaluation of target geriatric conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-emetic use
Endpoint domain: Adverse events/effects
Primary endpoint: Mean self-reported pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: 6-month progression free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Patient-reported discomfort from HHFNC O2
Endpoint domain: Adverse events/effects
Primary endpoint: Self-efficacy in managing symptoms (SEMS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-efficacy to managing diseases in general (SEMDG)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: prevalence of moderate/severe chronic gastritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: chronic gastritis activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: median number of incontinent episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median number of significant leaks per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total two-year costs of care per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Median time to cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loose stools per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: primary outcome measures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: History of fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Whole-body bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correct tourniquet application
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Knee Society Score (KSS) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ability to discriminate between behaviours and feelings
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Electrodiagnostic testing outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resistance training self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maximal observed drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic exposure (AUC(inf))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3 and 4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Breathlessness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: bimanual motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurological parkinsonian signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total transfused blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal blockage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power output during the 30-min TT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycogen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean cost per woman
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost per case of postpartum depression averted
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: perceived stress levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SF-8 Physical quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SF-8 Mental score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-assessed health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive function (word-list learning)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in word-list learning (delayed recall)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serum ARA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Baseline-adjusted BCVA at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: midfoot/forefoot dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalized vertical ground reaction force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum AhR-stimulating activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean hazing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain reported in nepafenac-treated eyes
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Quality of ovarian tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transmigration index of neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ≥2‐point improvement in glabellar line severity at maximum frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of patient's neuropsychiatric symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Caregiver's sense of competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowledge scores about HBV
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Narrow-walk speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite neuromuscular score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial injury as assessed by troponin I release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Collection of >/= 2.5 x 10(6) CD34(+) cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Circulating CD34(+) cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: need for repeat dose(s) of surfactant
Endpoint domain: Adverse events/effects
Primary endpoint: death or BPD
Endpoint domain: Mortality/survival
Primary endpoint: trunk fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Alcohol-related injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tinnitus Handicap Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hot flush severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration of gamma-tocopherol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma concentration of alpha-tocopherol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SCE rate and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear film BUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of air leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Annual per-patient cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Inpatient or ED visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Predicted average total costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increased lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical diagnosis of PsA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of myoinositol to creatine in occipital gray matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of myoinositol to creatine in frontal white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of choline to creatine in occipital gray matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean nocturnal SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of nocturnal desaturations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative sustained clinical success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from angiographic restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival with normal results of cranial computed tomography, electroencephalography and establishment of oral feeding by 14 days of age
Endpoint domain: Mortality/survival
Primary endpoint: Urinary nitrate elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Castelli risk index 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Castelli risk index 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-density lipoprotein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Local tolerability events
Endpoint domain: Adverse events/effects
Primary endpoint: mobility disability scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prediction probability for consciousness vs unconsciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual risk of thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PGC‐1α levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of Cave criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety or stress-related disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: epilepsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neuropathies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: renal recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean number of pain-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax and Cmin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disapproval of life-extending medical treatment for terminal patients suffering pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Opposition to life-extending medical intervention for patients in a vegetable state
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antral inflammation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gross gastroduodenal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serious extracranial hemorrhage requiring transfusion or hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Gastrointestinal hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral hemorrhage (intracranial hemorrhage)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall satisfaction with assistance received
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dietary Risk Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: log10 reduction in colony-forming units (cfu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients remaining free of VL at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Toxicity-related discontinuation of MTX
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of elevated liver enzyme levels
Endpoint domain: Adverse events/effects
Primary endpoint: Overall perioperative mortality
Endpoint domain: Mortality/survival
Primary endpoint: Actuarial survival at 12 and 24 months
Endpoint domain: Mortality/survival
Primary endpoint: horizontal resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: vertical reduction in the midcrestal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean airway pressure (Pmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tissue-handling skills improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decline in anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in rated acceptance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean INSL3 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: percentage of motile spermatozoa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Right-left EDA asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetry of information entropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cross-validated balanced accuracy (BAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Early visualization of the transverse sinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of DAVF type with reference standard study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demonstration of cortical venous reflux (CVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average urine output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H pylori eradication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes